NASDAQ: MBRXMoleculin Biotech Inc Stock
$4.83-1.80 (-27.15%)
Updated Dec 10, 2025
MBRX Price
$4.83
Fair Value Price
N/A
Market Cap
$9.84M
52 Week Low
$4.75
52 Week High
$91.25
P/E
-0.14x
P/B
-0.37x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$41.36M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.76
Operating Cash Flow
-$22M
Beta
0.87
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MBRX Overview
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MBRX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MBRX
Ranked#397 of 488
Ranked#397 of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $20.62 | A | |
| $322.68 | A | |
| $6.98 | A |
Be the first to know about important MBRX news, forecast changes, insider trades & much more!
MBRX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MBRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MBRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MBRX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
MBRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more MBRX due diligence checks available for Premium users.
Valuation
MBRX fair value
Fair Value of MBRX stock based on Discounted Cash Flow (DCF)
Price
$4.83
Fair Value
$1.10
Overvalued by
337.62%
MBRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MBRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.14x
Industry
163.89x
Market
46.23x
MBRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.37x
Industry
5.28x
MBRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$25.4M
Profit Margin
0%
MBRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$20.4M
Liabilities
$47.3M
Debt to equity
-1.76
MBRX's short-term assets ($7.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MBRX's long-term liabilities ($41.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MBRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MBRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.2M
Investing
$0.0
Financing
$6.4M
MBRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MBRX vs Biotech Stocks
Moleculin Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.